mRNA |
salermide:PLX-4032 (12:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.081 |
0.03 |
mRNA |
Cetuximab |
GDSC1000 |
pan-cancer |
AAC |
-0.069 |
0.03 |
mRNA |
lenalidomide |
GDSC1000 |
pan-cancer |
AAC |
-0.075 |
0.03 |
mRNA |
PLX4720 |
CTRPv2 |
pan-cancer |
AAC |
0.075 |
0.03 |
mRNA |
Compound 23 citrate |
CTRPv2 |
pan-cancer |
AAC |
0.071 |
0.03 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.078 |
0.03 |
mRNA |
BRD-K28456706 |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.03 |
mRNA |
SCH-79797 |
CTRPv2 |
pan-cancer |
AAC |
0.073 |
0.04 |
mRNA |
Bosutinib |
GDSC1000 |
pan-cancer |
AAC |
-0.068 |
0.04 |
mRNA |
BEC |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
0.04 |